RESEARCH ARTICLE

Influence of ACE I/D Polymorphism on Circulating Levels of Plasminogen Activator Inhibitor 1, D-Dimer, Ultrasensitive C-Reactive Protein and Transforming Growth Factor β1 in Patients Undergoing Hemodialysis

Sara Santos de Carvalho¹, Ana Cristina Simões e Silva², Adriano de Paula Sabino³, Fernanda Cristina Gontijo Evangelista⁴, Karina Braga Gomes⁵, Luci Maria Sant’Ana Dusse⁶, Danyelle Romana Alves Rios¹*

¹ Campus Centro Oeste Dona Lindu, Universidade Federal de São João del-Rei, Divinópolis/MG – Brazil, ² Department of Pediatrics, Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine – Universidade Federal de Minas Gerais, Belo Horizonte/MG – Brazil, ³ Department of Clinical and Toxicological Analysis, Faculty of Pharmacy - Universidade Federal de Minas Gerais, Belo Horizonte/MG – Brazil

* danyelleromana@gmail.com

Abstract

Background

There is substantial evidence that chronic renal and cardiovascular diseases are associated with coagulation disorders, endothelial dysfunction, inflammation and fibrosis. Angiotensin-Converting Enzyme Insertion/Deletion polymorphism (ACE I/D polymorphism) has also been linked to cardiovascular diseases. Therefore, this study aimed to compare plasma levels of ultrasensitive C-reactive protein (usCRP), PAI-1, D-dimer and TGF-β1 in patients undergoing HD with different ACE I/D polymorphisms.

Methods

The study was performed in 138 patients at ESRD under hemodialysis therapy for more than six months. The patients were divided into three groups according to the genotype. Genomic DNA was extracted from blood cells (leukocytes). ACE I/D polymorphism was investigated by single polymerase chain reaction (PCR). Plasma levels of D-dimer, PAI-1 and TGF-β1 were measured by enzyme-linked immunosorbent assay (ELISA), and the determination of plasma levels of usCRP was performed by immunonephelometry. Data were analyzed by the software SigmaStat 2.03.
Results
Clinical characteristics were similar in patients with these three ACE I/D polymorphisms, except for interdialytic weight gain. I allele could be associated with higher interdialytic weight gain (P = 0.017). Patients genotyped as DD and as ID had significantly higher levels of PAI-1 than those with II genotype. Other laboratory parameters did not significantly differ among the three subgroups (P = 0.033). Despite not reaching statistical significance, plasma levels of usCRP were higher in patients carrying the D allele.

Conclusion
ACE I/D polymorphisms could be associated with changes in the regulation of sodium, fibrinolytic system, and possibly, inflammation. Our data showed that high levels of PAI-1 are detected when D allele is present, whereas greater interdialytic gain is associated with the presence of I allele. However, further studies with different experimental designs are necessary to elucidate the mechanisms involved in these associations.

Introduction
Patients at end-stage renal disease (ESRD) undergoing dialysis therapy have increased morbidity and mortality compared with general population and approximately 40% of deaths in this population have been attributable to cardiovascular causes [1, 2]. Diabetes, hypertension, anemia, inflammation, vascular calcification, oxidative stress and alterations of the Renin Angiotensin System (RAS) are risk factors for cardiovascular disease (CVD) in patients under hemodialysis (HD) [2–5].

The RAS plays a central role in the regulation of blood pressure, hydroelectrolyte homeostasis and renal haemodynamics [2,3]. RAS mediators and enzymes have been linked to the pathogenesis of renal and cardiovascular diseases and also hypertension [3–5]. It is known that Angiotensin-Converting Enzyme (ACE) is a key enzyme in the RAS (zinc metallopeptidase) that converts angiotensin I to angiotensin II (Ang II) [6–8]. Angiotensin-Converting enzyme Insertion/Deletion polymorphism (ACE I/D polymorphism) is located in the intron of ACE gene and consists of either an insertion (I) allele or a deletion (D) allele leading to three possible genotypes: II, ID and DD. Human ACE gene is located in chromosome 17q23, where an insertion/deletion (I/D, dbSNP rs4646994) in intron 16 has been identified [9–11]. This polymorphism has been implicated in the development and progression of diabetic nephropathy, although conflicting results have been reported [12–14]. Furthermore, D allele of ACE I/D polymorphism has also been linked to cardiovascular diseases [15,16].

There is substantial evidence that chronic renal and cardiovascular diseases are associated with coagulation disorders, endothelial dysfunction, inflammation and fibrosis [17, 18]. In this regard, several markers of the fibrinolytic system and inflammation, such as D-dimer and C-reactive protein (CRP) exert a role in the pathogenesis of renal and cardiovascular disorders [19–21]. Elevated serum levels of CRP have been widely considered an important risk factor for atherosclerosis and coronary heart disease [22]. D-dimer is the smallest fibrin degradation product. Its plasma levels reflect either increase blood coagulation activation or fibrinolytic action pathway [19]. Considering fibrogenic markers, the transforming growth factor β1 (TGF-β1) is a multifunctional cytokine and key driver of fibrosis. It acts as a regulator of cell proliferation and collagen formation in cardiovascular and renal diseases [23, 24]. Plasminogen
activator inhibitor 1 (PAI-1), a potent regulator of fibrinolysis, has also been involved in several physiopathological processes. Depending on the disease, its overexpression or deficiency may trigger deleterious outcomes [25]. In addition, previous studies have shown interactions between ACE I/D polymorphism, RAS and fibrinolytic cascade [26,27].

In this context, it is reasonable to hypothesize that ACE I/D polymorphisms might be associated with differences in plasma levels of hemostatic and inflammatory parameters. Therefore, this study aimed to compare plasma levels of ultrasensible C-reactive protein (usCRP), PAI-1, D-dimer and TGF-β1 in patients undergoing HD with different ACE I/D polymorphisms.

**Patients and Methods**

**Patients**

This cross-sectional study was performed in patients at ESRD under hemodialysis therapy for more than six months. It was first made a detailed analysis of 344 medical records of patients undergoing hemodialysis in Hospital das Clínicas/Federal University of Minas Gerais (UFMG) and Instituto Mineiro de Nefrologia in Belo Horizonte/MG, Brazil. Among 344 patients, 138 were selected for study and 206 were excluded. Exclusion criteria were prescription of oral anticoagulation therapy, patients with acute or chronic hepatic disease, systemic lupus erythematosus, malignant cancer, vasculitis and acute infections, history of renal transplantation, HIV positive, pregnancy and oral contraceptive use in women.

After investigation of the ACE I/D polymorphism patients were divided into three groups according to the genotype: DD group (deletion/deletion ACE polymorphism); ID group (insertion/deletion ACE polymorphism); and II group (insertion/insertion ACE polymorphism).

Patients required regular hemodialysis sessions for 3–4 hours three times a week. Blood flow was usually 300-450mL/min with a dialysate flow at a constant rate of 500mL/min. All HD patients were dialyzed using low-flux polysulphone membranes and high-flow polysulphone membranes with bicarbonate-buffered dialysate. All patients received regular doses (100 a 150UI/kg/weight) of standard heparin before hemodialysis.

The Research Ethics Committee (COEP) of the Federal University of Minas Gerais approved study protocol (ETIC 099/07). All patients gave signed an informed consent term to participate in the study. Study protocol did not interfere with any medical prescription and/or recommendation.

**Assays**

Blood samples were drawn from hemodialysis vascular access before the beginning of dialysis session at the first session of the week. Blood samples were collected in 0.129 mol/L sodium citrate in 9:1 volume ratio and ethylene diamine tetraacetic acid 8% (EDTA 8%). Blood collected in citrate was centrifuged at 3,800 rpm for 20 min at 4°C to yield platelet poor plasma (PPP) and blood collected in EDTA was used for DNA extraction. Samples were aliquoted and stored at -70°C until analyzed. Plasma levels of D-dimer, PAI-1 and TGF-β1 were measured by enzyme-linked immunosorbent assay (ELISA) using commercially available kits from American Diagnostica-USA and R & D Systems-USA. The determination of plasma levels of ultrasensible CRP was performed by immunonephelometry, using the CardioPhase hsCRP (Dade Behring, Germany) kit, according to manufacturer's instructions.

**Investigation of ACE I/D polymorphism genotypes**

For investigation of the ACE I/D polymorphism, genomic DNA was extracted from blood cells (leukocytes), using the Wizard purification system (Promega Inc., Madison, WI, USA), following the manufacturer instructions.
ACE I/D polymorphism was investigated by single polymerase chain reaction (PCR). Briefly, ACE was obtained through one separate reaction, using oligonucleotides. The PCR primers were \(5'\) GCCCTGCAGGTGTCTGCAGCATGTG and \(5'\) GGATGGCTCTCCCGCCCTTGTCTCG (forward primer) and \(5'\) GCCCTGCAGGTGTCTGCAGCATGTG (reverse primer). Final volume of PCR reaction mixture was 20 μL that contained 1 mM of each primer (Invitrogen, São Paulo, SP, Brazil), 1.5 mM MgCl2, 0.2 mM of each deoxynucleoside triphosphate—dNTp (GIBCO BRL, São Paulo, SP, Brazil), 2.5 μL of 10X PCR Buffer and 0.5U of Taq polymerase (Phoneutria, Belo Horizonte, MG, Brazil).

Amplification was performed in a PT100 PCR thermocycler (MJ Research, Waltham, Massachusetts, USA) with initial denaturation step at 94°C for 2 min followed by 40 cycles consisting of denaturation at 94°C for 10 seconds, annealing at 60°C for 30 seconds and extension at 72°C for 30 seconds.

PCR products were separated on polyacrylamide gel 8% and DNA was visualized by silver nitrate. This gel was prepared with 15 mL of polyacrylamide solution, 129 μL of ammonium persulfate and 15 μL TEMED (N,N,N',N'-Tetramethylethylenediamine). DNA fragment sizes were 312 bp for the D allele and 599 bp for the I allele. Fragments displayed in the gels allowed to verify if the patient was heterozygous (ID: 599bp/312bp) or homozygous (II: 599bp and DD: 312bp). DNAs from previously typed individuals were included in each set of analyzed samples as control of enzyme activity (Fig 1).

Statistical analysis
Data were analyzed by the software SigmaStat 2.03. Normality of variable distribution was checked using Kolmogorov-Smirnov test. Gaussian variables were reported as mean ± standard deviation (SD) and non-Gaussian variables as medians and interquartile range (IQ, percentile 25 and percentile 75). Analysis of variance (ANOVA) or Kruskal-Wallis test and Dunn post-test were used to compare differences between groups. p-values lower than 0.05 were considered statistically significant.

Results
Among the total of 138 patients, 80 (58%) had DD genotype, 42 (30.4%) had ID genotype and 16 (11.6%) had II genotype. Clinical characteristics were similar in patients with these three genotype of ACE I/D polymorphisms, except for interdialytic weight gain (IDWG) (Table 1). Regarding the age, DD, ID and II patients had mean age of 50, 53 and 51 years, respectively. Most patients were males and mean body mass index (BMI) of the subgroups DD, ID and II were, respectively, 23.2, 24.1 and 23.2 kg/m2. In all subgroups, hypertensive nephrosclerosis was the main primary cause of chronic kidney disease (CKD).

Laboratory parameters did not significantly differ among the three subgroups (Table 2), except for PAI-1 levels (Fig 2). Patients genotyped as DD (median of 12.1 ng/mL and IQ of 5.6–20.4 ng/mL) and as ID (median of 15.8 ng/mL and IQ of 4.6–27.1 ng/mL) had significantly higher levels of PAI-1 than those with II genotype (median 4.9 ng/mL and IQ of 2.4–10.9 ng/mL, p = 0.033, Fig 2). Despite not reaching statistical significance, usCRP levels were higher in patients carrying the D allele as shown in Table 2.

Discussion
We examined the association between ACE I/D polymorphism and clinical, hemostatic and inflammatory parameters in ESRD patients. Concerning clinical and epidemiological data, the only variable that differed according to ACE I/D polymorphism is IDWG. Our data shown that the presence of I allele is associated with higher IDWG, being 3,500g in ID and 3,325g in...
II versus 2,890g in patients with DD genotype. These findings may suggest an association between IDWG and I allele. IDWG, a measurement of HD compliance, is the result of salt and water intake between two dialysis sessions. In the literature there are two main causes that lead to the IDWG: nutritional status (calorie and protein intake) and water and salt intake [28]. In this study, in regard to the nutritional status, serum albumin and normal protein catabolism rate (nPCR) did not significantly differ among the three subgroups. Several studies have reported a relationship between ACE I/D polymorphism and salt sensitivity [29]. Salt sensitivity is a measure of how blood pressure responds to salt intake. Almost 50% of essential hypertension is salt sensitivity, and this has been linked to an increased risk of cardiovascular events [30]. A positive association between I allele and salt sensitivity was previously found in essential hypertensive patients [31–33]. It means that the same amount of sodium intake produced a more pronounced increase in blood pressure in individuals with I allele. In our study we did not evaluate the relationship between ACE I/D polymorphism and salt sensitivity. However, we hypothetize that higher IDWG in patients who carry the allele I may be due to a higher sensitivity to the amount of sodium intake.

Our data showed that PAI-1 levels were significantly higher in patients carrying the D allele (DD and ID groups) compared to others without this allele (II group). According to our data,
the same association between DD genotype and high PAI-1 levels was previously observed [34, 35]. We did not investigate the mechanisms beyond this association. However, one possible explanation is that our patients with D allele probably have higher levels and activity of ACE, as previously reported in other studies [11, 36, 37]. Costerousse et al. showed that T-lymphocyte levels of ACE were significantly higher in healthy subjects with D/D ACE polymorphism than in subjects with other genotypes [38]. Indeed, the I/D polymorphism accounted for 47% of the total phenotypic variance of serum ACE, showing that the ACE gene locus is the major locus that determines serum ACE concentration [11]. In addition, several studies suggest a link between RAS and fibrinolytic system [39]. Ridker et al. and Yamamoto et al. [39, 40] proposed that high levels of ACE are associated with an increase in tissue conversion of angiotensin I (Ang I) into angiotensin II (Ang II). It was also observed that the DD genotype is associated with the enhanced conversion of Ang I to Ang II probably as a result of higher levels and activity of ACE [41]. Then, Ang II is enzymatically converted to angiotensin IV by aminopeptidases.
ACE I/D Polymorphism was studied frequently in cardiovascular diseases. Ishimitsu et al. [1] showed that D allele of the ACE gene polymorphism is an independent risk factor for cardiovascular diseases in long-term hemodialysis patients. Additionally, it has been shown that dialysis patients have an increase in PAI-1 levels, which becomes them vulnerable to cardiovascular risk [44, 25]. Guney et al. [45] showed that the ACE D allele and DD genotype were the major risk factors for coronary heart disease (CAD). Several studies have also revealed that ACE and PAI-1 play a role in CAD occurrence, since both molecules have a critical role in atherosclerosis and hypertension [46–48].

Previous studies emphasize RAS as a major contributor to hypertension [49, 50]. Besides it is associated with chronic inflammation in tissues and organs involved in key participants

Table 2. Hemostatic and inflammatory parameters in different genotype groups for ACE I/D polymorphism.

| Parameters             | DD group (n = 80) | ID group (n = 42) | II group (n = 16) | P value |
|------------------------|------------------|------------------|------------------|---------|
| Erythrocytes x10^6/mL | 4.0 ± 0.6        | 4.0 ± 0.6        | 4.2 ± 0.7        | 0.464   |
| Hemoglobin (g/dL)      | 12.5 (11.1–13.4) | 12.1 (11–13.8)  | 13.0 (11.1–13.9) | 0.776   |
| Hematocrit (%)         | 37.5 (34–40.8)   | 36.7 (33.2–41.2) | 39.1 (33.4–41.2) | 0.677   |
| Serum albumin          | 3.5 (3.3–3.7)    | 3.4 (3.3–3.6)    | 3.3 (3.1–3.8)    | 0.165   |
| nPCR                   | 1.1 (0.9–1.4)    | 1.1 (1.0–1.2)    | 0.9 (0.7–1.6)    | 0.503   |
| PAI-1 (ng/mL)          | 12.1 (5.6–20.4)  | 15.8 (4.6–27.1)  | 4.9 (2.4–10.9)   | 0.033** |
| D-Di (ng/mL)           | 466.1 (250.2–813.8) | 447.1 (278.7–1012) | 387.3 (176.3–623.5) | 0.420   |
| TGF-β1 (pg/mL)         | 2740.6 (2195.6–3270.2) | 2585.3 (2134.7–3395.6) | 2544.6 (2149.8–3003) | 0.633   |
| usCRP (mg/L)           | 4.5 (2–9.6)      | 3.5 (1.6–9.7)    | 1.6 (0.7–5.3)    | 0.067   |

**P < 0.05 DD x II and ID x II. The normally distributed data were expressed as mean ± SD (ANOVA). The non-Gaussian data were presented as median (range interquartile). (Kruskal Wallis test). Frequencies (%) were evaluated by χ² test. DD group: deletion/deletion group. ID group: insertion/deletion group. II group: insertion/insertion group. nPCR: normal protein catabolism rate; PAI-1: Plasminogen activator inhibitor type 1; D-Di: D-dimer; TGF-β1: Transforming growth factor-β1; usCRP: ultrasensitive C-reative protein.

doi:10.1371/journal.pone.0150613.t002

(localized on the endothelial surface), increasing the endothelial PAI-1 expression [39, 42, 43]. Lamentely, we were not able to confirm this hypothesis since ACE activity and/or Ang II levels were not measured in our patients.

ACE gene I/D polymorphism was studied frequently in cardiovascular diseases. Ishimitsu et al. [1] showed that D allele of the ACE gene polymorphism is an independent risk factor for cardiovascular diseases in long-term hemodialysis patients. Additionally, it has been shown that dialysis patients have an increase in PAI-1 levels, which becomes them vulnerable to cardiovascular risk [44, 25]. Guney et al. [45] showed that the ACE D allele and DD genotype were the major risk factors for coronary heart disease (CAD). Several studies have also revealed that ACE and PAI-1 play a role in CAD occurrence, since both molecules have a critical role in atherosclerosis and hypertension [46–48].

Previous studies emphasize RAS as a major contributor to hypertension [49, 50]. Besides it is associated with chronic inflammation in tissues and organs involved in key participants

![Fig 2. Distribution of PAI-1 (ng/mL) plasma levels in groups DD, ID and II. The horizontal lines indicate the medians obtained.](https://example.com/figure2.png)

doi:10.1371/journal.pone.0150613.g002
of blood pressure regulation, such as the kidneys and vessels [51]. Therefore, individuals who have the D would have more chances to develop hypertension and this increased pressure would lead to endothelial damage in parallel to the onset of inflammation. In this present study, we obtained a borderline P-value for usCRP levels increase (P = 0.067), and the highest levels were found in patients with the D allele compared to homozygous patients for the allele I.

CPR is produced by the liver under the control of various proinflammatory cytokines. usCRP is used as a marker of infection or activity parameter of ongoing inflammatory disease in ESRD patients [49]. It has been recognized that about 30–50% of predialysis and HD patients have serological evidence of an activated inflammatory response, which can be related to renal failure and may be a consequence of the dialysis process [50]. The bioincompatibility of dialysate, exposure of circulating mononuclear cells to the dialysis membrane, vascular access, may all be factors that enhance inflammation in HD patients [51]. Evidence from experimental and clinical studies has been accumulating that usCRP is not only a marker of inflammation but also contribute directly to the pathogenesis of atherosclerosis and its complications through a variety of mechanisms [52]. This led to the hypothesis of an accelerated atherogenesis in patients on dialysis. Moreover, CRP induces the synthesis and physiological functions of PAI-1 in the endothelium [53].

The RAS also has a direct influence on the progression of the atherosclerotic process via effects on endothelial function, inflammation, fibrinolytic balance, and plaque stability [54]. Therefore, the presence of D allele may be related to greater chance of developing atherosclerosis. We might speculate a relationship between ACE I/D polymorphism and PAI-1 levels in our study, since the levels of this marker are increased in patients who have the D allele (DD and ID groups) compared to patients without the D allele (II group). Thus, it is possible that patients who carrying the D allele have an increased chance of developing arteriosclerosis and other cardiovascular diseases compared to those without this allele.

In conclusion, this study suggests that ACE I/D polymorphisms could be associated with changes in the regulation of sodium, fibrinolytic system, and possibly, inflammation. Our data showed that high levels of PAI-1 are detected when D allele is present, whereas greater interdialytic gain is associated with the presence of I allele. However, further studies with different experimental designs are necessary to elucidate the mechanisms involved in these associations.

Author Contributions

Conceived and designed the experiments: SSC ACSS FCGE KBG LMSD DRAR. Performed the experiments: SSC APS FCGE DRAR. Analyzed the data: SSC ACSS DRAR. Contributed reagents/materials/analysis tools: ACSS APS LMSD DRAR. Wrote the paper: SSC ACSS APS FCGE LMSD DRAR.

References

1. Ishimitsu T, Tsukada K, Ohta S, Inada H, Minami J, Ono H, et al. Increased Cardiovascular Risk in Long-Term Hemodialysis Patients Carrying Deletion Allele of ACE Gene Polymorphism. American Journal of Kidney Diseases, 2004; 44:466–475. PMID: 15332219
2. Jablonski LK, Chonchol M. Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease. F1000Prime Reports 2014; 6:72. doi: 10.12703/P6-72 PMID: 25165571
3. Kim S, Iwao W. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11–34. PMID: 10699153
4. Alvarez R, Requero JR, Bataila A, Iglesias-Cubero G, Cortina A, Alvarez V, et al. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res 1998; 40:375–379. PMID: 9999731
5. Pontremoli R, Ravera M, Viazzì F, Nicolella C, Berruti V, Leoncini G, et al. Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension. Kidney Int 2000; 57: 561–569. PMID: 10652033

6. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000; 36: 449–467. PMID: 10977776

7. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977; 57:313–370. PMID: 191856

8. Corvol P, Williams TA, Soubrier F. Peptidyl dipeptidase A: angiotensin I-converting enzyme. Methods Enzymol 1995; 248:283–305. PMID: 7674927

9. Yaren A, Oztop I, Turgut S, Turgut G, Degirmencioglu S, Demirpence M. Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer. Exp Biol Med (Maywood) 2008; 233: 32–37.

10. Tronvik E, Stovner LJ, Bovim G, White LR, Gladwin AJ, Owen K, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. BMC Neurol 2008; 8: 4. doi: 10.1186/1471-2377-8-4 PMID: 18366776

11. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86(4):1343–1346. PMID: 1976655

12. Taal MW. Angiotensin-converting enzyme gene polymorphisms in renal disease: clinically relevant? Curr Opin Nephrol Hypertens 2000; 9:651–7. PMID: 11128428

13. Marre M, Bernardet P, Gallois Y, Savagner F, Guyene TT, Hallab M, et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic renal and vascular complications. Diabetes 1994; 43:384–8. PMID: 8314010

14. Kunz R, Bork JP, Fritsche L, Ringel J, Sharma AM. Association between the angiotensin-converting enzyme insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review. J Am Soc Nephrol 1998; 9:1653–63. PMID: 9727374

15. Samani NJ, Thompson JR, O’Toole L, Chanter K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94:708–712, 1996. PMID: 8772692

16. Mallamaci F, Zuccala A, Zoccali C, Testa A, Gaggi R, Spoto B, et al. The deletion polymorphism of the angiotensin-converting enzyme is associated with nephroangiosclerosis. Am J Hypertens 2000; 13:433–437. PMID: 10821348

17. Sabovic M, Salobir B, Zupan IP, Bratina P, Bojec V, Ponikvar JB. The Influence of the Haemodialysis Procedure on Platelets, Coagulation and Fibrinolysis. Pathophysiol Haemost Thromb 2005; 34:274–278. PMID: 16772739

18. Dusse ML, Rios DRA, Pinheiro MB, Cooper AJ, Bashir A, Lwaleed BA. Pre-eclampsia: Relationship between coagulation, fibrinolysis and inflammation. Clinica Chimica Acta 2011; 412:17–21.

19. Milburn JA, Ford I, Mutch NJ, Fluck N, Brittenden J. Thrombin-Anti-Thrombin Levels and Patency of Arterio-Venous Fistula in Patients Undergoing Haemodialysis Compared to Healthy Volunteers: A Prospective Analysis. PLoS ONE 2013; 8(7): e67799. doi: 10.1371/journal.pone.0067799 PMID: 23844096

20. Oda H, Ohno M, Ohashi H. Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease. Adv Perit Dial 2000; 16: 152–155. PMID: 11045282

21. Kirmizis D, Tsandoulas A, Pangalou M, Koutoupa E, Rozi P, Protopappa M, et al. Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis. Med Sci Monit 2006; 12: R55–R62.

22. Shah PK. Circulating markers of inflammation for vascular risk prediction: are they ready for prime time? Circulation. 2000; 101:1758–1759. PMID: 10769272

23. Agarwal I, Glazer NL, Barasch E, Biggs ML, Djussé L, Fitzpatrick AL, et al. Fibrosis-Related Biomarkers and Risk of Total and Cause-Specific Mortality - The Cardiovascular Health Study. Am J Epidemiol. 2014; 179(11):1331–1339. doi: 10.1093/aje/kwu067 PMID: 24771724

24. Rosenberg MA, Maziarz M, Tan AY, Glazer NL, Zieman SJ, Kizer JR, et al. Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS). American Heart Journal, 167 (5): 723–728. doi: 10.1016/j.ahj.2014.01.010 PMID: 24766983

25. Małgorzewicz S, Jankun S, Jankun J. Plasminogen activator inhibitor-1 in kidney pathology (Review). International Journal of Molecular Medicine. 2013; 31: 503–510. doi: 10.3892/ijmm.2013.1234 PMID: 23314920
26. Moore JH, Smolkin ME, Lamb JM, Brown NJ, Vaughan DE. The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms. Clin Genet 2002; 62: 53–59. PMID: 12123488

27. Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, et al. Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. Genomics 2007; 89: 362–369. PMID: 17207964

28. Gómez JML, Villaverde M, Jofre R, Benítez PR, García RP. Interdialytic weight gain as a marker of blood pressure, nutrition, and survival in hemodialysis patients. Kidney International, 2005; 67(93): S63–S68.

29. Caprioli J, Mele C, Mossali C, Gallizioti L, Giacchetti G, Noris M, et al. Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertension. Canadian Journal of Physiology and Pharmacology, 2008; 86:505–510. doi: 10.1139/Y08-045 PMID: 18758497

30. Franco V, Oparil S. Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival. J. Am. Coll. Nutr., 2006; 25 (3 Suppl): 247S–255S. PMID: 16772636

31. Hiraga H, Oshima T, Watanabe M, Ishida M, Ishida T, Shingu T, et al. Angiotensin I-converting enzyme gene polymorphism and salt sensitivity in essential hypertension. Hypertension 1996; 27:569–572. PMID: 8613205

32. Giner V, Poch E, Bragulat E, Oriola J, González D, Coca A, et al. Renin-Angiotensin System Genetic Polymorphisms and Salt Sensitivity in Essential Hypertension. 2000; 35(2):512–517.

33. Yamagishi K, Tanigawa T, Cui R, Tabata M, Ikeda A, Yao M, et al. High Sodium Intake Strengthens the Renin-Angiotensin System and Fibrinolytic Function. Circulation 1993; 87: 1969

34. Margaglione M, Cappucci G, Giuliani N, Vecchione G, Di Minno G. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998; 18:562. PMID: 9555861

35. Kim DK, Ryu JC, Rhee CH, Lee WR. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 1997; 17:3242. PMID: 9409318

36. Zhang Z, Xu G, Liu D, Fan X, Zhu W, Liu X. Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism Contributes to Ischemic Stroke Risk: A Meta-Analysis of 50 Case-Control Studies. PLoS ONE 2012; 7(10): e46495. doi: 10.1371/journal.pone.0046495 PMID: 23049705

37. Munhouz T, Schei R, Schmitt V. Angiotensin converting enzyme (ACE) DD genotype: relationship with venous thrombosis. Rev. bras. hematol. hemoter. 2005; 27(2):87–90.

38. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J. 1993 Feb 15; 290 (Pt 1):33–40. PMID: 8382480

39. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969–1973. PMID: 8504511

40. Yamamoto K, Takeshita K, Tetsuhito K, Takamatsu J, Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res 2005; 66:276–85. PMID: 15820196

41. Ueda S, Elliott HL, Morton JJ, Connel JMC. Enhanced pressor response to angiotensin I in normotensive men with the ACE deletion allele. Hypertension. 1995; 25:1266–1269. PMID: 7788572

42. Felmenden DC, Lip GYH. The renin-angiotensin-aldosterone system and fibrinolysis. Journal of the Renin-Angiotensin-Aldosterone System; 2000; 1:240–4. PMID: 11881031

43. Vaughan DE, Lazos S, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-type 1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95(3):995–1001. PMID: 7884001

44. Arikan H, Koc M, Tuglular S, Ozenner C, Akoglu E. Elevated plasma levels of PAI-1 predict cardiovascular and cardiac events and cardiovascular mortality in prevalent peritoneal dialysis patients. Ren Fail 2009; 31: 438–445. PMID: 19839820

45. Guney AI, Ergec D, Kirac D, Ozturhan H, Caner M, Koc G, et al. Effects of ACE polymorphisms and other risk factors on the severity of coronary artery disease. Genetics and Molecular Research 2013; 12 (4): 6895–6906. doi: 10.4237/2013.DECember.19.8 PMID: 24391037

46. Sakkthie M, Poopak B, Amirizadeh N, Shamsheir A, Bagheri A, Faranoush M (2014) Polymorphism and synergism of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) genes in coronary artery disease. Journal of the Renin-Angiotensin-Aldosterone System; 1–7.
47. Aucella F, Margaglione M, Vigiante M, Gatta G, Grandone E, Forcella M, et al. PAI-1 4G/5G and ACE I/D gene polymorphisms and the occurrence of myocardial infarction in patients on intermittent dialysis. Nephrol Dial Transplant 2003; 18: 1142–1146 PMID: 12748347

48. Hamstein A, deFaire U, Walldius G, Dahlén G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk for recurrent myocardial infarction. Lancet 1987; 2: 3–9. PMID: 2885513

49. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001; 59: 407–414. PMID: 11168922

50. Stenvinkel P. Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 2002; 17: 33–38.

51. Suliman ME, Stenvinkel P. Contribution of inflammation to vascular disease in chronic kidney disease patients. Saudi J Kidney Dis Transpl 2008; 19: 329–345. PMID: 18445891

52. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165–2168. PMID: 11056086

53. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398–404. PMID: 12551862

54. Husain K, Hernandez W, Ansari AR, Ferder L. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem 2015; 6(3): 209–217. doi: 10.4331/wjbc.v6.i3.209 PMID: 26322175